Investigator-Initiated Trial

NBM-BMX is a novel chemical entity designed to selectively inhibit histone deacetylase 8 (HDAC8). While non-selective HDAC inhibitors face limitations in clinical applications due to significant side effects, the development of isoform-selective inhibitors like NBM-BMX offers a promising alternative. NBM-BMX has demonstrated potent anti-proliferative effects across various cancer cell types, particularly in tumors with elevated HDAC8 expression.

NBM-BMX is a novel chemical entity designed to selectively inhibit histone deacetylase 8 (HDAC8). While non-selective HDAC inhibitors face limitations in clinical applications due to significant side effects, the development of isoform-selective inhibitors like NBM-BMX offers a promising alternative. NBM-BMX has demonstrated potent anti-proliferative effects across various cancer cell types, particularly in tumors with elevated HDAC8 expression.